Biocon’s path-breaking work in novel biologics and novel targets in large molecules has seen significant results in diabetes, oncology and immunology. The novel biologics portfolio includes both, in-house as well as partnered and in-licensed products.
CONTACT
Group Companies
NOVEL BIOLOGICS
Enabling cutting edge therapies
Bicara Therapeutics, an associate of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates our development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.
global innovations
In-house research capabilities
Access to novel IP, therapeutic modalities, in-vivo and in-vitro models
Toxicology studies
Early regulatory filings
Academic collaborations
novel assets
Monoclonal antibodies against novel targets like CD6, against established targets like CD20 and EGFR
Bispecific fusion antibodies that explore the role of checkpoint inhibitors
Insulin Tregopil, our orally delivered insulin analog, that is making clinical progress
Novels Biologics
BUSINESS INTENT
create market leadership in innovation e.g. Insulin Tregopil, Itolizumab
PIPELINE
oral insulin, mAbs against targets like CD6, CD20 & EGFR; bi-specific fusion mAbs
POTENTIAL
to change the treatment paradigm in diabetes, inflammation and auto-immunology
Biocon & Novels
We are the pioneers in developing, manufacturing and launching BIOMAb-EGFR®, India’s first indigenously produced novel monoclonal antibody for the treatment of head and neck cancer; and ALZUMAb™, the world’s first novel anti-CD6 monoclonal antibody in India, for psoriasis.
Novels In Pipeline
Our novel biologics under clinical development focus on treatments in diabetes, autoimmune/ inflammation and oncology. These represent a combination of early and advanced stage assets.
Know more
about us
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
